Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Velcade Bortezomib Multiple Myeloma Reimburse Complete
Velphoro sucroferric oxyhydroxide Hyperphosphatemia, end-stage renal disease Reimburse with clinical criteria and/or conditions Complete
Velsipity etrasimod Ulcerative colitis Reimburse with clinical criteria and/or conditions Active
Veltassa patiromer Hyperkalemia, adults (chronic kidney disease) Reimburse with clinical criteria and/or conditions Complete
Vemlidy tenofovir alafenamide Hepatitis B, chronic Reimburse with clinical criteria and/or conditions Complete
Venclexta venetoclax Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Venclexta venetoclax Acute myeloid leukemia Do not reimburse Complete
Venclexta Venetoclax Chronic Lymphocytic Leukemia Reimburse with clinical criteria and/or conditions Complete
Venclexta Venetoclax Withdrawn
Venclexta venetoclax Chronic lymphocytic leukemia (CLL) Active